APYX Q3 2024: 25% Workforce Cut and $4M Cost Reduction Extend Runway, Set Up Aon Launch
APYX Medical’s Q3 marked a decisive pivot, with a 25% US workforce reduction and $4 million in new cost savings to extend cash runway and reposition for the Aon system launch in 2025. While capital equipment sales remain pressured by macro headwinds and GLP-1 drug trends, recurring disposable revenue and OEM growth are stabilizing the base. The company’s execution on cost, capital, and product pipeline will be critical as it aims to transition from restructuring to renewed growth in surgical aesthetics.
Summary
- Restructuring Drives Cost Reset: US workforce reduced by 25%, board shrunk, and OPEX targeted below $40M in 2025.
- Disposable Revenue Offsets Capital Weakness: Recurring handpiece sales and OEM growth stabilize the business amid generator softness.
- Aon Platform Launch Is Central to Growth Narrative: All-in-one surgical system aims to reignite equipment sales and market share in 2025 and beyond.
Business Overview
APYX Medical develops and commercializes energy-based medical devices for surgical aesthetics, with two primary segments: Advanced Energy (Renuvion, disposable handpieces, and generators for skin tightening and body contouring) and OEM (contract manufacturing for third-party medical device companies). Revenue is generated through capital equipment sales, recurring sales of single-use handpieces, and OEM manufacturing contracts. The company’s flagship technology, Renuvion, is FDA-cleared for loose skin procedures, and it is building toward the launch of the Aon integrated body contouring platform.
Performance Analysis
APYX delivered Q3 revenue of $11.5 million, down 4% YoY, driven by continued softness in capital equipment sales but partially offset by recurring disposable revenue and OEM growth. The Advanced Energy segment declined 6% as generator sales weakened, reflecting macroeconomic pressure and a slowdown in elective procedures due to GLP-1 drug adoption. However, disposable handpiece revenue, a higher-margin recurring stream, grew 9% globally and 15% in the US, now comprising over 60% of AE revenue. OEM sales increased 3%, providing a stabilizing contribution.
Gross margin compressed to 60.5% (from 66.6%) due to lower generator ASPs, unfavorable segment mix, and higher international sales. Operating expenses fell 16% to $10.6 million, reflecting aggressive cost control, including the elimination of bonuses and a focus on reducing SG&A. The company’s net loss widened slightly to $4.7 million, but adjusted EBITDA loss improved by 20% to $2.4 million. Cash used in operations was flat YoY after adjusting for a prior tax refund, and the balance sheet was bolstered by a $7M direct investment from Nantahala Capital Management.
- Recurring Revenue Strength: Disposable handpiece sales are now the majority of AE revenue, providing resilience against capital cycle volatility.
- OEM Segment Grows: OEM manufacturing, while smaller, posted 3% YoY growth and is expected to remain a stable contributor.
- Margin Pressure Persists: Lower ASPs and mix shift continue to weigh on gross margin, highlighting the need for product mix improvement post-Aon launch.
Cost actions and new capital have extended APYX’s cash runway into 2027, but near-term growth remains dependent on recurring revenue and successful execution on the Aon platform launch.
Executive Commentary
"Under the restructuring, APEX reduced its US workforce by nearly 25%. As part of the reduction, Todd Hornsby, Executive Vice President of Sales and Marketing, will be leaving the company effective immediately...We carefully evaluated our options and determined that this restructuring was needed to right-side the business."
Stavros Vazirianakis, Executive Chairman
"Our disposable handpiece revenue grew 9% overall and 15% in the United States...Disposable revenue now accounts for more than 60% of our total AE revenue...We are excited to announce the Apix team is in the final stages of developing the Aon body contouring system...We believe Aon is a game-changer for surgeons that will differentiate us and position Apix as their surgical partner."
Charlie Goodwin, President & Chief Executive Officer
Strategic Positioning
1. Cost Structure Reset and Board Realignment
APYX is executing a deep cost restructuring, cutting 25% of its US workforce and reducing board size from eight to five. This is paired with a significant reduction in board compensation and OPEX targets below $40 million for 2025, down from $53 million in 2023. These moves are designed to align the organization’s scale with current market realities and extend cash runway.
2. Recurring Revenue Focus and Disposable Penetration
The shift toward disposable handpiece revenue is central to APYX’s near-term strategy. With procedural volumes pressured, disposables provide a more stable, high-margin revenue stream. The company is leveraging direct-to-consumer and physician education campaigns to drive adoption and reinforce Renuvion as the standard of care for loose skin, particularly among GLP-1 drug users experiencing rapid weight loss.
3. Product Pipeline and Aon Platform Launch
The upcoming Aon system, an integrated surgical platform, is positioned as a major growth catalyst. It combines Renuvion, multiple liposuction modalities, and fat transfer into a single device, aiming to become the centerpiece of surgical practices. The Aon system requires the Apex One generator, incentivizing both upgrades and new system sales. FDA 510(k) submission is planned by Q1 2025, with commercial launch targeted for the second half of 2025.
4. Capital and Covenant Management
APYX strengthened its balance sheet with a $7M direct investment and renegotiated debt covenants with Perceptive Advisors, lowering revenue targets and adding OPEX caps for 2025-26. These changes provide flexibility amid near-term revenue softness and reinforce discipline around cash burn.
5. Commercial Execution and Leadership Changes
CEO Charlie Goodwin now directly oversees sales, with a new COO promoted from R&D to focus on operational execution. The restructuring is intended to streamline decision-making and maintain commercial momentum as the company prepares for the Aon launch.
Key Considerations
This quarter was a turning point, as APYX undertook aggressive restructuring to align with persistent market headwinds and prepare for a new product cycle. The company’s ability to stabilize recurring revenue, execute on cost, and deliver the Aon platform will determine its trajectory over the next 12 to 18 months.
Key Considerations:
- Disposable Revenue as Shock Absorber: Recurring handpiece sales now anchor the business, offsetting capital sales cyclicality and supporting margin stability.
- Aon System as Growth Catalyst: The integrated platform could reignite capital sales and expand APYX’s share of the surgical aesthetics market if execution and physician adoption meet expectations.
- Cost Discipline Is Non-Negotiable: Substantial OPEX reduction is required to achieve cash flow break-even and meet revised debt covenants.
- GLP-1 Drug Trend Creates Tailwind and Challenge: While procedural volumes are pressured short term, the surge in loose skin patients could drive demand for APYX’s solutions if the company wins physician mindshare.
Risks
APYX faces continued demand softness in capital equipment, with macroeconomic uncertainty and GLP-1 adoption delaying elective procedures. The success of the Aon launch is not assured, and any regulatory, commercialization, or adoption delays could extend the growth trough. Margin recovery depends on product mix improvement, and further pricing pressure or competitive launches could weigh on profitability. Debt covenants and cash burn remain critical watchpoints if revenue does not rebound as projected.
Forward Outlook
For Q4 and full-year 2024, APYX guided to:
- Total revenue of $46.6M to $47.6M, down 11% to 9% YoY
- Advanced Energy revenue of $37.2M to $38.2M, down 14% to 12% YoY
- OEM revenue of ~$9.4M, up 5% YoY
For full-year 2025, management expects:
- Total revenue of $47.6M to $49.5M, up 2% to 6% YoY
- Advanced Energy revenue up 5% to 7% YoY
- OEM revenue down 10% YoY as ordering normalizes
- Operating expenses capped at $40M
Management emphasized recurring disposable growth, strict cost controls, and the Aon launch as keys to achieving these targets and extending cash runway into 2027.
- Handpiece growth and Aon adoption are expected to drive incremental revenue in 2025.
- Cost savings fully phased in by Q1 2025, supporting margin and cash flow improvement.
Takeaways
APYX is aggressively restructuring to weather near-term headwinds and position for a new product cycle. Investors should watch disposable revenue trends, Aon platform milestones, and execution on cost discipline as leading indicators of turnaround potential.
- Recurring Revenue Anchors Stability: Handpiece sales and OEM growth are absorbing some of the capital equipment drag, but margin recovery depends on mix improvement post-Aon launch.
- Cost Actions Provide Runway: The reset of OPEX and board structure is substantial, but must be matched by revenue execution to avoid further cash burn or covenant stress.
- Aon Launch Is Make-or-Break: The integrated system’s market acceptance and commercialization pace will determine whether APYX can return to sustainable growth in 2025 and beyond.
Conclusion
APYX Medical’s third quarter was defined by decisive cost action and strategic repositioning. The company’s future hinges on the successful launch and adoption of the Aon system, continued growth in recurring disposables, and disciplined execution on cost and capital. The next 12 months will be pivotal for both operational turnaround and long-term competitive positioning.
Industry Read-Through
APYX’s experience reflects broader pressures in the surgical aesthetics and medical device sector, where elective procedure volumes remain volatile and GLP-1 trends reshape patient pathways. Recurring disposable revenue is increasingly critical for device makers facing capital cycle slowdowns. The pivot toward integrated, multifunction platforms (as with Aon) signals a trend toward consolidation of surgical tools and workflow simplification—an approach likely to be emulated by competitors. Cost discipline and balance sheet flexibility are becoming prerequisites for survival, especially for smaller players with concentrated product portfolios. The coming year will test which firms can translate cost resets and pipeline launches into durable market share gains.